These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
73 related articles for article (PubMed ID: 20351030)
1. Predicting outcomes and drug resistance with standardised treatment of active tuberculosis. Oxlade O; Schwartzman K; Pai M; Heymann J; Benedetti A; Royce S; Menzies D Eur Respir J; 2010 Oct; 36(4):870-7. PubMed ID: 20351030 [TBL] [Abstract][Full Text] [Related]
2. Predicting outcomes and drug resistance with new standardised treatment. Mohapatra PR; Hari DT Eur Respir J; 2011 Apr; 37(4):974; author reply 974-5. PubMed ID: 21454904 [No Abstract] [Full Text] [Related]
3. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis]. Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568 [TBL] [Abstract][Full Text] [Related]
4. Influence of multidrug resistance on tuberculosis treatment outcomes with standardized regimens. Mak A; Thomas A; Del Granado M; Zaleskis R; Mouzafarova N; Menzies D Am J Respir Crit Care Med; 2008 Aug; 178(3):306-12. PubMed ID: 18511706 [TBL] [Abstract][Full Text] [Related]
5. [Effects of two treatment regimens for drug-resistant tuberculosis in tuberculosis control project areas: a comparative study]. Li L; Zheng SH; Chu NH; Xie YG; Yang YZ; Li Q; Wang XM; Yan XL; Tan WG; Miao ZP; Duanmu HJ Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(48):3387-91. PubMed ID: 19159566 [TBL] [Abstract][Full Text] [Related]
6. Revised Category II regimen as an alternative strategy for retreatment of Category I regimen failure and irregular treatment cases. Tabarsi P; Chitsaz E; Tabatabaei V; Baghaei P; Shamaei M; Farnia P; Marjani M; Kazempour M; Mansouri D; Masjedi MR; Velayati AA Am J Ther; 2011 Sep; 18(5):343-9. PubMed ID: 20535008 [TBL] [Abstract][Full Text] [Related]
7. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months. Nolan CM; Goldberg SV Int J Tuberc Lung Dis; 2002 Nov; 6(11):952-8. PubMed ID: 12475140 [TBL] [Abstract][Full Text] [Related]
8. A case series: initial outcome of persons with multidrug-resistant tuberculosis after treatment with the WHO standard retreatment regimen in Ho Chi Minh City, Vietnam. Lan NTN ; Lademarco MF; Binkin NJ; Tung LB; Quy HT; Cĵ NV Int J Tuberc Lung Dis; 2001 Jun; 5(6):575-8. PubMed ID: 11409587 [TBL] [Abstract][Full Text] [Related]
9. Development of acquired drug resistance in recurrent tuberculosis patients with various previous treatment outcomes. Yoshiyama T; Yanai H; Rhiengtong D; Palittapongarnpim P; Nampaisan O; Supawitkul S; Uthaivorawit W; Mori T Int J Tuberc Lung Dis; 2004 Jan; 8(1):31-8. PubMed ID: 14974743 [TBL] [Abstract][Full Text] [Related]
10. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis. Park SK; Kim JH; Kang H; Cho JS; Smego RA Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342 [TBL] [Abstract][Full Text] [Related]
11. Tuberculosis retreatment category predicts resistance in hospitalized retreatment patients in a high HIV prevalence area. Schreiber YS; Herrera AF; Wilson D; Wallengren K; Draper R; Muller J; Dawood H; Doucette S; Cameron DW; Alvarez GG Int J Tuberc Lung Dis; 2009 Oct; 13(10):1274-80. PubMed ID: 19793433 [TBL] [Abstract][Full Text] [Related]
12. First-line anti-tuberculosis drug resistance patterns and trends at the national TB referral center in Iran--eight years of surveillance. Shamaei M; Marjani M; Chitsaz E; Kazempour M; Esmaeili M; Farnia P; Tabarsi P; Amiri MV; Mirsaeidi M; Mansouri D; Masjedi MR; Velayati AA Int J Infect Dis; 2009 Sep; 13(5):e236-40. PubMed ID: 19285897 [TBL] [Abstract][Full Text] [Related]
13. Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis. Becerra MC; Freeman J; Bayona J; Shin SS; Kim JY; Furin JJ; Werner B; Sloutsky A; Timperi R; Wilson ME; Pagano M; Farmer PE Int J Tuberc Lung Dis; 2000 Feb; 4(2):108-14. PubMed ID: 10694087 [TBL] [Abstract][Full Text] [Related]
14. Comparing cost-effectiveness of standardised tuberculosis treatments given varying drug resistance. Law S; Benedetti A; Oxlade O; Schwartzman K; Menzies D Eur Respir J; 2014 Feb; 43(2):566-81. PubMed ID: 23766335 [TBL] [Abstract][Full Text] [Related]
15. Latent tuberculosis infection in children: a call for revised treatment guidelines. Finnell SM; Christenson JC; Downs SM Pediatrics; 2009 Mar; 123(3):816-22. PubMed ID: 19255008 [TBL] [Abstract][Full Text] [Related]
16. Clinical and operational value of the extensively drug-resistant tuberculosis definition. Migliori GB; Besozzi G; Girardi E; Kliiman K; Lange C; Toungoussova OS; Ferrara G; Cirillo DM; Gori A; Matteelli A; Spanevello A; Codecasa LR; Raviglione MC; Eur Respir J; 2007 Oct; 30(4):623-6. PubMed ID: 17690121 [TBL] [Abstract][Full Text] [Related]
17. [The short-term and long-term treatment outcomes in patients with pulmonary tuberculosis positive for drug-resistant and sensitive strains]. Han JP; Sun SL; Li RZ; Zhang FS; Wang SC; Cheng J; Deng YF; Wang Y; Yu CB Zhonghua Jie He He Hu Xi Za Zhi; 2003 Feb; 26(2):70-3. PubMed ID: 12783654 [TBL] [Abstract][Full Text] [Related]
18. [Research and control of relapse tuberculosis cases]. Yamagishi F; Toyota M Kekkaku; 2009 Dec; 84(12):767-8. PubMed ID: 20077861 [TBL] [Abstract][Full Text] [Related]
19. The management of tuberculosis: epidemiology, resistance and monitoring. Bang D Dan Med Bull; 2010 Nov; 57(11):B4213. PubMed ID: 21055374 [TBL] [Abstract][Full Text] [Related]
20. Preventing drug-resistant tuberculosis with a fixed dose combination of isoniazid and rifampin. Moulding TS; Le HQ; Rikleen D; Davidson P Int J Tuberc Lung Dis; 2004 Jun; 8(6):743-8. PubMed ID: 15182145 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]